RESEARCH & DEVELOPMENT

Harnessing powerful molecules for powerful therapies

Research and development is vital for professionals and patients in the critical care community. The unmet needs of critically ill patients are a powerful motivator for the scientists of Ikaria. Investigating the potential additional benefits of INOMAX^® (nitric oxide) for inhalation is an ongoing journey. And, we are aggressively pursuing the development of new critical care therapies across the spectrum of drugs and drug delivery system combinations.

Where it all begins

Our preclinical discovery and exploratory research facility is located in Seattle, WA. We are equipped and staffed to conduct state-of-the-art synthetic chemistry, analytical and bioanalytical chemistry, formulation, pharmacology, and toxicology studies. This is where ideas are born.

Molecules that are critical to critical care
Our drug development program runs deep and has roots in endogenous signalling molecules. These molecules are naturally produced by the body and are powerful influencers of many cellular functions. These include nitric oxide (NO) and hydrogen sulfide (H₂S).^1-5 Recent discoveries show that these naturally occurring molecules—when delivered properly in low doses—may demonstrate several essential critical care benefits.

New on the horizon
We are also investigating the therapeutic potential of terlipressin, a special modified form of another endogenous molecule, the vasoconstrictor hormone vasopressin.⁶ We have also recently acquired several exclusive worldwide licenses. IK-5001* is a potential treatment for preventing pathological cardiac remodeling following acute myocardial infarction.^†7 Ikaria is also focusing on investigational fibrin-derived compounds IK-600X portfolio,^‡ which are being studied to preserve endothelial barrier function, prevent tissue injury,^† and are being investigated in a multitude of critical care conditions.^8,9